Ixico secures two clinical trial contracts worth £1.3m

Ixico has secured two new clinical trial contracts in neurological disorders with a combined value of about £1.3m, it announced on Friday, extending its presence in both Alzheimer’s disease and rare central nervous system conditions.

The AIM-traded firm said the first agreement, with an unnamed major pharmaceutical company, covered trial management and imaging analysis for a phase 1 Alzheimer’s disease study over a period of around three and a half years.

It said the second, with an unidentified US-based biotech, would see Ixico support high-quality imaging data collection for a phase 1b trial in Friedreich’s ataxia to aid surgical planning, in a collaboration expected to run for six years.

“The contract wins underline the innovative, adaptable and agile nature of the Ixico platform and our teams as irrefutable thought leaders in the neurodegenerative disease space,” said chief executive Bram Goorden.

“The two deals hit different key elements of our strategy, respectively supporting Alzheimer’s as a core indication, and maintaining our leadership position in the rare CNS disease space.”

Ixico said the wins reflected continued progress in its ‘innovate, lead, scale’ strategy aimed at driving global expansion and growth in neuroscience imaging and biomarker analytics.

At 0826 BST, shares in Ixico were up 0.17% at 12.02p.

Reporting by Josh White for Sharecast.com.